NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
G100 advancing to late-stage development following FDA feedback Conference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today
View HTML
Toggle Summary Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif. , July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report second quarter 2018 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma
- G100 directly targets and modifies TLR4 expressing malignant B cells making them more visible to the anti-tumor immune response- SEATTLE and SOUTH SAN FRANCISCO, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on novel therapies in
View HTML
Toggle Summary Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global Healthcare Conference in New York
SEATTLE and SOUTH SAN FRANCISCO, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that the company will host an event featuring key opinion leaders in the cancer immunotherapy landscape on
View HTML
Toggle Summary Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
          -- 1 st global Phase 3 trial focused on synovial sarcoma patients SYNOVATE is a randomized, global Phase 3 trial to evaluate CMB305 immuontherapy in synovial sarcoma patients. www.synovatestudy.com           --  www.synovatestudy.com SEATTLE and SOUTH SAN FRANCISCO, Calif., May 24, 2018
View HTML
Toggle Summary Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3 The 20ug dose of G100 shows a two-fold increase in TILs, higher than that seen at the 10ug dose Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif. , April 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report first quarter 2018 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
-   New positive clinical and translational data for both lead agents -   Strong balance sheet with 2017 year-end cash and equivalents of $144.2 Million -   Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif. , March 14, 2018 (GLOBE NEWSWIRE) -- Immune Design
View HTML
Toggle Summary Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
Median overall survival of 23.7 months following CMB305 monotherapy represents approximately one-year extension of survival compared to published data in soft tissue sarcoma patient population Objective response rate (ORR) for follicular lymphoma patients treated with G100 and pembrolizumab
View HTML
Toggle Summary Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif. , March 07, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report fourth quarter and year end 2017 financial results after the close of U.S.
View HTML